Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Metabolic screening after the American Diabetes Association's consensus statement on antipsychotic drugs and diabetes.

Morrato EH, Newcomer JW, Kamat S, Baser O, Harnett J, Cuffel B.

Diabetes Care. 2009 Jun;32(6):1037-42. doi: 10.2337/dc08-1720. Epub 2009 Feb 24.

2.

Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs.

Morrato EH, Druss B, Hartung DM, Valuck RJ, Allen R, Campagna E, Newcomer JW.

Arch Gen Psychiatry. 2010 Jan;67(1):17-24. doi: 10.1001/archgenpsychiatry.2009.179.

PMID:
20048219
3.
4.

Metabolic risk status and second-generation antipsychotic drug selection: a retrospective study of commercially insured patients.

Morrato EH, Cuffel B, Newcomer JW, Lombardo I, Kamat S, Barron J.

J Clin Psychopharmacol. 2009 Feb;29(1):26-32. doi: 10.1097/JCP.0b013e31819294cb.

PMID:
19142103
5.

[Drawing up guidelines for the attendance of physical health of patients with severe mental illness].

Saravane D, Feve B, Frances Y, Corruble E, Lancon C, Chanson P, Maison P, Terra JL, Azorin JM; avec le soutien institutionnel du laboratoire Lilly.

Encephale. 2009 Sep;35(4):330-9. doi: 10.1016/j.encep.2008.10.014. Epub 2009 Jul 9. French.

PMID:
19748369
6.

Metabolic screening in children receiving antipsychotic drug treatment.

Morrato EH, Nicol GE, Maahs D, Druss BG, Hartung DM, Valuck RJ, Campagna E, Newcomer JW.

Arch Pediatr Adolesc Med. 2010 Apr;164(4):344-51. doi: 10.1001/archpediatrics.2010.48. Erratum in: Arch Pediatr Adolesc Med. 2010 Jun;164(6):584.

PMID:
20368487
7.

Metabolic monitoring of patients prescribed second-generation antipsychotics.

Dhamane AD, Martin BC, Brixner DI, Hudson TJ, Said Q.

J Psychiatr Pract. 2013 Sep;19(5):360-74. doi: 10.1097/01.pra.0000435035.45308.03.

PMID:
24042242
8.

Assessment of monitoring for glucose and lipid dysregulation in adult Medi-Cal patients newly started on antipsychotics.

Barnett M, VonMuenster S, Wehring H, Popish S, McDonald K, Walker VM, Perry P.

Ann Clin Psychiatry. 2010 Feb;22(1):9-18.

PMID:
20196978
9.

Predictors of metabolic monitoring among schizophrenia patients with a new episode of second-generation antipsychotic use in the Veterans Health Administration.

Shi L, Ascher-Svanum H, Chiang YJ, Zhao Y, Fonseca V, Winstead D.

BMC Psychiatry. 2009 Dec 18;9:80. doi: 10.1186/1471-244X-9-80.

10.

Quality of monitoring for metabolic effects associated with second generation antipsychotics in patients with schizophrenia on public insurance.

Moeller KE, Rigler SK, Mayorga A, Nazir N, Shireman TI.

Schizophr Res. 2011 Mar;126(1-3):117-23. doi: 10.1016/j.schres.2010.11.015. Epub 2010 Dec 18.

PMID:
21168994
11.

Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents.

Haupt DW, Rosenblatt LC, Kim E, Baker RA, Whitehead R, Newcomer JW.

Am J Psychiatry. 2009 Mar;166(3):345-53. doi: 10.1176/appi.ajp.2008.08030383. Epub 2009 Jan 15.

PMID:
19147694
12.

Diabetes and lipid screening among patients in primary care: a cohort study.

Rifas-Shiman SL, Forman JP, Lane K, Caspard H, Gillman MW.

BMC Health Serv Res. 2008 Jan 30;8:25. doi: 10.1186/1472-6963-8-25.

13.

Retrospective analysis of diabetes care in California Medicaid patients with mental illness.

Banta JE, Morrato EH, Lee SW, Haviland MG.

J Gen Intern Med. 2009 Jul;24(7):802-8. doi: 10.1007/s11606-009-0994-9. Epub 2009 May 5.

14.

[Metabolic testing rates after initiation of antipsychotic treatment in persons initially treated by conventional mood-stabilizers].

Verdoux H, Gaudron Y, Auleley GR, Deligne J, Blum-Boisgard C, ThiƩbaut A, Tournier M.

Encephale. 2013 May;39 Suppl 1:S22-8. doi: 10.1016/j.encep.2012.10.009. Epub 2012 Dec 13. French.

PMID:
23246328
15.

Evaluation of a computer-based intervention to enhance metabolic monitoring in psychiatry inpatients treated with second-generation antipsychotics.

DelMonte MT, Bostwick JR, Bess JD, Dalack GW.

J Clin Pharm Ther. 2012 Dec;37(6):668-73. doi: 10.1111/j.1365-2710.2012.01369.x. Epub 2012 Jul 30.

16.

Changes in neuroendocrine and metabolic hormones induced by atypical antipsychotics in normal-weight patients with schizophrenia.

Popovic V, Doknic M, Maric N, Pekic S, Damjanovic A, Miljic D, Popovic S, Miljic N, Djurovic M, Jasovic-Gasic M, Dieguez C, Casanueva FF.

Neuroendocrinology. 2007;85(4):249-56. Epub 2007 Jun 15.

PMID:
17570902
17.

Metabolic monitoring for youths initiating use of second-generation antipsychotics, 2003-2011.

Connolly JG, Toomey TJ, Schneeweiss MC.

Psychiatr Serv. 2015 Jun;66(6):604-9. doi: 10.1176/appi.ps.201400222. Epub 2015 Mar 1.

PMID:
25726977
18.

Measurement of Metabolic Monitoring in Youth and Adult Medicaid Recipients Prescribed Antipsychotics.

Edelsohn GA, Parthasarathy M, Terhorst L, Karpov IO, Schuster J.

J Manag Care Spec Pharm. 2015 Sep;21(9):769-77, 777a-777cc.

19.

Metabolic Testing for Adults in a State Medicaid Program Receiving Antipsychotics: Remaining Barriers to Achieving Population Health Prevention Goals.

Morrato EH, Campagna EJ, Brewer SE, Dickinson LM, Thomas DS, Miller BF, Dearing J, Druss BG, Lindrooth RC.

JAMA Psychiatry. 2016 Jul 1;73(7):721-30. doi: 10.1001/jamapsychiatry.2016.0538.

PMID:
27167755
20.

Naturalistic impact of second-generation antipsychotics on weight gain.

Brixner DI, Said Q, Corey-Lisle PK, Tuomari AV, L'italien GJ, Stockdale W, Oderda GM.

Ann Pharmacother. 2006 Apr;40(4):626-32. Epub 2006 Mar 28.

PMID:
16569802

Supplemental Content

Support Center